Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

AI Search Startup Exa Labs Raises $250M At $2.2 Billion Valuation, Led By Andreessen Horowitz

View original at finance.yahoo.com
AI Search Startup Exa Labs Raises $250M At $2.2 Billion Valuation, Led By Andreessen Horowitz Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Exa's crawlers index more than 500 billion URLs and the company has developed its own vector database to support high query volumes.

    60% confidence

  • Exa Labs will use new capital to train its next generation of models and expand infrastructure capable of handling hundreds of thousands of searches per second.

    60% confidence

  • Exa's search tools are used by more than 400,000 developers.

    60% confidence

  • Competitors built on top of existing search engines will struggle to match Exa's combination of speed, cost efficiency, and retrieval quality.

    60% confidence

  • AI-driven search demand will surge as more autonomous agents come online.

    60% confidence

  • Building a perfect search engine will be extremely hard. It is also necessary. Information is critical civilizational infrastructure for our new AI reality. If we can build perfect search so that every AI has the highest quality information, then every human will too.

    60% confidence

  • Different AI agents require different retrieval behavior — from go-to-market tools needing broad coverage of people and organizations, to coding assistants relying on precise results from repositories and technical documentation.

    60% confidence

  • Exa Labs usage has grown to more than 5,000 businesses since pivoting to an API-first model in early 2023.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com